Zhejiang Jingxin Pharmaceutical (002020) Stock Overview

Zhejiang Jingxin Pharmaceutical Co., Ltd. researches and develops, produces, and sells pharmaceutical products and medical devices in China. The company offers antihypertensive, antibiotics, quinolones, gastrointestinal promotion, antidiabetic, antiepileptic, antihistamine, H+ pump depressant, antihyper cholesterolemia, histamine H2 receptor blockader, antihyper cholesterolemirs, antidepressant, Cephalosporin, and biopharma products; and API products, including ciprofloxacin, ciprofloxacin hydrochloride, ciprofloxacin lactate, levofloxacin hemihydrate, levofloxacin hydrochloride, levofloxacin lactate, enrofloxacin, enrofloxacin hydrochloride, simvastatin, rosuvastatin calcium, pitavastatin calcium, sitagliptin, clopidogrel bisulfate, ticagrelor, rivaroxaban, apixaban, sisapele, esomeprazole, levetiracetam, bovaracetam, sertraline hydrochloride, pramipexole hydrochloride, rivastigmine bitartrate, memantine hydrochloride, and paliperidone. It also provides intermediates; and medical display products, such as diagnostic medical displays, surgical medical displays, clinical medical displays, medical large screens, medical integrated machines, and ultrasonic medical displays. The company was formerly known as Zhejiang Jingxin Pharmaceutical Factory and changed its name to Zhejiang Jingxin Pharmaceutical Co., Ltd. in 2000. Zhejiang Jingxin Pharmaceutical Co., Ltd. was founded in 1990 and is headquartered in Xinchang, China.